|
 |
AlfuzosinThis page contains recent news articles, when available, and an overview of Alfuzosin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Alfuzosin (when available) Alfuzosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Alfuzosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Alfuzosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Alfuzosin results from a decrease in systemic vascular resistance and the parent compound Alfuzosin is primarily responsible for the antihypertensive activity. For the treatment of the signs and symptoms of benign prostatic hyperplasia Mechanism Of Action: Alfuzosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. News Articles on Alfuzosin Torrent Pharma gets tentative USFDA nod for Alfuzosin Hydrochloride - Dec 14, 2009 Drug maker, Torrent Pharmaceuticals has received tentative approval from US Food and Drug Administration (USFDA) for Alfuzosin Hydrochloride. ... Myiris.com Sanofi-Aventis: near-term benign prostatic hyperplasia prospects look bleak - Dec 21, 2009 With the licensing deal for cetrorelix, Sanofi-Aventis aimed to protect and consolidate its share of the BPH market after the expiry of Xatral (alfuzosin) ... Trading Markets (press release) Sanofi Uroxatral Promotion Gets Untitled Letter - Nov 5, 2009 The agency's Division of Drug Marketing, Advertising and Communications says the promotional materials for Uroxatral (alfuzosin HCl) extended-release ... FDA news (subscription) Uroxatral Risks Not Adequately Disclosed in Advertisements: FDA Warns - Oct 29, 2009 Uroxatral (alfuzosin) is a prostate drug that is only approved to treat an enlarged prostate, known as benign prostatic hyperplasia. ... AboutLawsuits.com 1- Adrenergic Blockers and Intraoperative Floppy-Iris Syndrome - Nov 9, 2009 ...(tamsulosin and silodosin) are much more commonly associated with the development of IFIS than the 1 -blockers terazosin, doxazosin, and alfuzosin. ... Archives of Ophthalmology FDA, 사노피 ì „ë¦½ì„ ë¹„ëŒ€ì•½ ìš°ë¡œìž?트랄 íŒ?ì´‰ ê²½ê³ - Nov 1, 2009 ...김윤ì˜? 기ìž? FDA는 사노피-아벤티스사ì?˜ ì „ë¦½ì„ ë¹„ëŒ€ì¦? 치료약 ìš°ë¡œìž?트랄(Uroxatral: alfuzosin)ì—? 대한 íŒ?촉물ì—?ì„œ 오ë?„하는 표현ì?„ 지ì ?í•˜ê³ ê²½ê³ ì„œì‹ ì?„ 회사ì—? ... 메디포뉴스 Brand Names/Synonyms: Alfuzosin is also known by the following brand names and/or synonymsUroxatral; Xatral Drug Category: Alfuzosin is categorized under the following by the FDA: Antihypertensive Agents; Unclassified Therapeutic Agents (92:00.00); ATC:G04CA01 Dosage Forms: TABLET (EXTENDED-RELEASE) Absorption: Absorption is 50% lower under fasting conditions Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]propyl]tetrahydrofuran-2-carboxamide |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
